What changed in 3M Company's latest annual report
In the year ended 31 Dec 2025, 3M Company's revenue rose 1.5% to USD 24.95bn, from USD 24.57bn; net income fell 22.1% to USD 3.25bn, from USD 4.17bn; shareholders' equity rose 22.4% to USD 4.70bn, from USD 3.84bn.
Year ended 31 Dec 2025. Source: 10-K filed 3 Feb 2026, read it on SEC EDGAR.
USD 24.57bn to USD 24.95bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 24.57bn | 24.95bn | Up 1.5% |
| Net income | 4.17bn | 3.25bn | Down 22.1% |
| Total assets | 39.87bn | 37.73bn | Down 5.4% |
| Total liabilities | 35.97bn | 32.99bn | Down 8.3% |
| Long-term debt | 11.13bn | 10.93bn | Down 1.7% |
| Shareholders' equity | 3.84bn | 4.70bn | Up 22.4% |
Questions people ask
Did 3M Company's revenue grow last year?
Revenue grew 1.5%, from USD 24.57bn to USD 24.95bn in the year ended 31 Dec 2025.
Is 3M Company profitable?
Yes. Net income was USD 3.25bn in the year ended 31 Dec 2025. The year before: USD 4.17bn.
How much cash and debt does 3M Company have?
At its latest year end (31 Dec 2025), 3M Company reported long-term debt of USD 10.93bn.
Where do these numbers come from?
From 3M Company's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with 3M Company?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%
- Solventum CorporationNet income up 224.8%